Abstract
Cell lines resistant to five antitumor alkylating agents (CDDP, PAM, 4-HC, HN2, and BCNU) were developed from five parental human tumor lines representative of solid tumors with a range of sensitivities to antitumor alkylating agents. The parental cell lines were SCC-25 squamous carcinoma of the head and neck, MCF-7 breast carcinoma, SW2 small-cell lung cancer, SL6 non-small-cell lung carcinoma, and G3361 melanoma. Survival curves using colony formation as the endpoint were generated for each of the 25 cell lines to each of the five alkylating agents. Comparison of the drug concentrations that reduced the survival of the alkylating agent-resistant cell lines by 90% (IC90 values) with the IC90 values obtained for the corresponding parental cell lines was used as a measure of the resistance/sensitivity of the alkylating agent-resistant lines to each drug tested. Although cross-resistance among the alkylating agents was generally uncommon, several patterns of response emerged. Cross-resistance occurred in 27 of the 105 determinations and occurred most frequently in the cell lines in which resistance was developed to PAM (57%) or BCNU (38%). Cross-resistance to HN2 occurred most frequently. Collateral sensitivity was equally as common, occurring in 25 of the 105 determinations. Collateral sensitivity occurred most frequently in the cell lines made resistant to 4-HC. The 4-HC-resistant cell lines were most frequently collaterally sensitive to PAM and to BCNU. Cross-resistance developed most frequently in the MCF-7 breast carcinoma and SCC-25 squamous-cell carcinoma cell lines, whereas collateral sensitivity developed most frequently in the SW2 small-cell lung cancer line and the G3361 melanoma cell line and least frequently in the MCF-7 breast carcinoma cell line and the SL6 non-small-cell lung cancer cell line. The implication of these findings for the development of strategies for clinical treatment are discussed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- AAs:
-
antitumor alkylating agents
- CDDP:
-
cisplatin,cis-diamminedichloroplatinum(II)
- HN2:
-
nitrogen mustard
- BCNU:
-
N,N′-bis(2-chloroethyl)-N-nitrosourea
- PAM:
-
l-phenylalanine mustard, melphalan
- 4-HC:
-
4-hydroxyperoxycyclophosphamide
- CPA:
-
cyclophosphamide
- THIO:
-
trimethyleneiminethiophosphoramide
- DME:
-
Dulbecco's modified Eagle's medium
- IC90 :
-
90% inhibitory concentration
- PBS:
-
phosphate-buffered 0.9% saline
- FBS:
-
fetal bovine serum
- GSH:
-
glutathione
- GST:
-
glutathione-S-transferase
References
StatXact Statistical package (1992) CYTEL Software Corporation, Cambridge, Massachusetts
Anderson KC (1992) Neoplasms of the hematopoietic system. In: Holland JF, Frei E III, Kufe D, Morton DL, Weichselbaum RR (eds) Cancer medicine. Lea and Febiger, Philadelphia, pp 2075–2091
Blum R, Frei E III (1979) Combination chemotherapy: methods in cancer research. Cancer Res 17: 215–257
Blum RH, Garnick MB, Israel M, Canellos GP, Henderson IC, Frei E III (1981) Preclinical rationale and phase I clinical trial of the Adriamycin analog, AD32. Recent results. Cancer Res 76: 7–15
Chabner BA (1990) In defense of cell line screening. J Natl Cancer Inst 82: 1083–1085
Curt GA, Clendeninn NJ, Chabner BA (1984) Drug resistance in cancer. Cancer Treat Rep 68: 87–99
Dorr RT, Fritz WL (1980) Cancer chemotherapy handbook. Elsevier, New York
Draper N, Smith H (1981) Applied regression analysis, 2nd edn. John Wiley, New York
Eder JP, Antman K, Peers W, Henner WD, Eilas A, Shea TC, Schryber S, Anderson J, Come S, Schnipper L, Frei E III (1986) High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 4: 1592–1597
Fisher B, Oxborne CK, Margolese R, Bloomer WD (1992) Neoplasms of the Breast. In: Holland JF, Frei E III, Kufe D, Morton DL, Weichselbaum RR (eds) Cancer medicine. Lea and Febiger, Philadelphia, pp 1706–1774
Francis J, Bernal SD, Gazdar AF, Thompson R, Baylin S (1980)l-Dopa decarboxylase activity (DDC): a distinguished biomarker for the growth of small cell lung cancer (SCCL) in tissue culture. Proc Am Assoc Cancer Res 21: 52
Francis K, Thompson R, Bernal SD, Luk G, Baylin SA (1983) Effects of dibutyral adenosine 3′,5′-monophosphate on growth of cultured human small cell lung carcinoma and the specific cellular activity ofl-dopa decarboxylase. Cancer Res 43: 639–645
Frei E III (1972) Combination cancer therapy: presidential address. Cancer Res 32: 2593–2607
Frei E III (1985) Curative cancer chemotherapy. Cancer Res 45: 6523–6537
Frei E III, Antman KH (1992) Principles of chemotherapy. In: Holland JF, Frei E III, Kufe D, Morton DL, Weichselbaum RR (eds) Cancer medicine. Lea and Febiger, Philadelphia, pp 631–639
Frei E III, Canellos GP (1980) Dose, a critical factor in cancer chemotherapy. Am J Med 69: 585–594
Frei E III, Cucchi CA, Rosowsky A, Tantravahi R, Bernal S, Erwin TJ, Ruprecht RM, Haseltine WA (1985) Alkylating agent resistance: in vitro studies with human cell lines. Proc Natl Acad Sci USA 82: 2158–2162
Frei E III, Karon M, Levin RH, Freireich EJ, Taylor RJ, Hananian J, Selawry O, Holland JF, Hoogstraten B, Wolman IJ, Abir E, Sawitsky A, Lee S, Mills SD, Burgert EO Jr, Spurr CL, Patterson RB, Ebaugh FG, James GW III, Moon JH (1965) The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 26: 642–656
Frei E III, Teicher BA, Cucchi CA, Rosowsky A, Flatow JL, Kelley MJ, Genereux P (1988) Resistance to alkylating agents: basic studies and therapeutic implications. In: Woolley PVI, Tew KD (eds) Mechanisms of drug resistance in neoplastic cells. Academic Press, New York, pp 69–87
Frei E III, Teicher BA, Holden SA, Cathcart KNS, Wang Y (1988) Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 48: 6417–6423
Goldenberg GJ, Begeleiter A (1979) Membrane transport of alkylating agents. Pharmacol Ther 8: 237–274
Goldenberg GJ, Vanstone CL, Israels LG, Ilse D, Bihler I (1970) Evidence for a transport carrier of nitrogen mustard in nitrogen mustard-sensitive and-resistant L5178 lymphoblasts. Cancer Res 30: 2285–2291
Hall TC (1986) Cancer drug resistance. Alan R. Liss, New York
Holland JF (1983) Breaking the cure barrier. J Clin Oncol 1: 75–90
Lampidis TJ, Bernal SD, Summerhays IC, Chen LB (1983) Selective toxicity of rhodamine 123 in carcinoma cells in vitro. Cancer Res 43: 716–720
Lehman EL (1975) Nonparametrics: statistical methods based on ranks. Holden-Day, San Francisco
Liu LF (1989) DNA topoisomerase poisons as anti-tumor drugs. Annu Rev Biochem 58: 351–375
Morton DL, Kirkwood JM, Parker RG, Wong JH (1992) Malignant melanoma. In: Holland JF, Frei E III, Kufe D, Morton DL, Weichselbaum RR (eds) Cancer medicine. Lea and Febiger, Philadelphia, pp 1793–1824
Pegg AE (1990) MammalianO6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50: 6119–6129
Peters WP, Eder JP, Henner WD, Schryber S, Wilmore D, Finberg R, Schoenfeld D, Bast R, Gargone B, Antman K, Anderson J, Anderson K, Kriskall MS, Schnipper L, Frei E III (1986) High dose combination alkylating agents with autologous bone marrow support: a phase I trial. J Clin Oncol 4: 646–654
Phillips GL, Fay JW, Herzig GP, Herzig RH, Weiner RS, Wolff SN, Lazarus HM, Karanes C, Ross WE, Kramer BS (1983) Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC 4366650 and cryopreserved autologous marrow transplantation for refractory cancer. Cancer 10: 1792–1802
Redwood WR, Colvin M (1980) Transport of melphalan by sensitive and resistant L1210 cells. Cancer Res 40: 1144–1149
Rheinwald JG (1980) Serial cultivation of normal human epidermal keratinocytes. Methods Cell Biol 21: 229–254
Rheinwald JG, Beckett MA (1981) Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas. Cancer Res 41: 1657–1663
Schabel FM, Griswold DP, Corbett TH, Laster WR (1983) Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Pharmacol Therap 20: 283–305
Schabel FM Jr, Griswold DP Jr, Corbett TH, Laster WR Jr, Mayo JG, Lloyd HH (1979) Testing therapeutic hypotheses in mice and man: observations on the therapeutic activity against advanced solid tumors of man. Methods Cancer Res 17: 3–51
Schabel FMJ, Trader MW, Laster WRJ, Wheeler GP, Witt MH (1978) Patterns of resistance and therapeutic synergism among alkylating agents. Antiobiotics Chemother 23: 200–215
Scudiero D, Meyer S, Clatterbuck B, et al (1984) Sensitivity of human cell strains having different abilities to repairO6-methylguanine in DNA to inactivation by alkylating agents including chloroethylnitrosoureas. Cancer Res 44: 2467
Skipper HE (1974) Combination therapy: some concepts and results. Chemother Rep 4: 137–145
Sladek NE (1988) Metabolism of oxazaphosphorines. Pharmacol Ther 37: 301–355
Snedecor GW, Cochran WG (1989) Statistical methods, 8th edn. Iowa State University Press, Ames, Iowa
Summerhayes IC, Lampidis TJ, Bernal SD, Nadakavukaren JJ, Nadakavukaren KK, Shepard EL, Chen LB (1982) Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells. Proc Nat Acad Sci USA 79: 5292–5296
Teicher BA, Cucchi CA, Lee JB, Flatow JL, Rosowsky A, Frei E III (1986) Alkylating agents: in vitro studies of cross-resistance patterns. Cancer Res 46: 4379–4383
Teicher BA, Frei E III (1988) Development of alkylating agent resistant human tumor cell lines. Cancer Chemother Pharmacol 21: 292–298
Teicher BA, Frei E III (1989) Alkylating agents. In: Gupta RS (ed) Drug resistance in mammalian cells: anticancer and other drugs. CRC Press, Boca Raton, pp 1–31
Teicher BA, Holden SA, Herman TS, Alvarez Sotomayor E, Khandekar V, Rosbe KW, Brann TW, Korbut TT, Frei E III (1991) Characteristics of five human tumor cell lines and sublines resistant tocis-diamminedichloroplatinum(II). Int J Cancer 47: 252–260
Teicher BA, Holden SA, Kelley MJ, Shea TC, Cucchi CA, Rosowsky A, Henner WD, Frei E III (1987) Characterization of a human squamous carcinoma cell line resistant tocis-diamminedichloroplatinum(II). Cancer Res 47: 388–393
Thomas ED (1982) The role of marrow transplantation in the eradication of malignant disease. Cancer 49: 1963–1969
Vistica DT, Toal JN, Rabinowitz M (1978) Amino acid conferred protection against melphalan. Characterization of melphalan transport and correlation of uptake with cytotoxicity in cultured L1210 murine leukemia cells. Biochem Pharmacol 27: 2865
Walton MI, Whysong D, O'Connor PM, Korsmeyer SJ, Hockenberry D, Kohn KW (1992) Constitutive overexpression of Bcl-2 in murine lymphocytes imparts partial protection to DNA damage induced apoptosis. Cancer Res 33: 150
Wang Y, Teicher BA, Shea TC, Holden SA, Rosbe KW, Al-Achi A, Henner WD (1989) Cross-resistance and glutathione-S-transferase-ϕ levels among four human melanoma cell lines selected for alkylating agent resistance. Cancer Res 49: 6185–6192
Waud WR (1992) Therapeutic resistance in leukemia. In: Teicher BA (ed) Drug resistance in oncology. Marcel Dekker, New York, pp 227–250
Waxman DJ (1990) Glutathione-S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy, a review. Cancer Res 50: 6449–6454
Wick MM (1979) 3,4-Dihydrobenzylamine: a dopamine analog with enhanced antitumor activity against B16 melanoma. J Natl Cancer Inst 63: 1465–1472
Wolf GT, Lippman SM, Laramore GE, Hong WK (1992) Neoplasms of the head and neck. In: Holland JF, Frei E III, Kufe D, Morton DL, Weichselbaum RR (eds) Cancer medicine. Lea and Febiger, Philadelphia, pp 1211–1274
Wooley PV, Tew KD (1988) Mechanisms of drug resistance in neoplastic cells. Academic Press, San Diego
Author information
Authors and Affiliations
Additional information
This work was supported by NIH grant PO1-38493, by a grant from the Mathers Foundation, by a grant from Bristol-Myers-Squibb, Inc., Wallingford, Connecticut, and by ACS grant CH-487
Rights and permissions
About this article
Cite this article
Frei, E., Holden, S.A., Gonin, R. et al. Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies. Cancer Chemother. Pharmacol. 33, 113–122 (1993). https://doi.org/10.1007/BF00685328
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685328